Pharmaron Beijing Co Ltd (300759) — Working Capital to Net Assets Ratio
Pharmaron Beijing Co Ltd (300759) has a Working Capital to Net Assets ratio of 17.3% as of September 2025. Working capital of CN¥2.62 Billion (current assets of CN¥7.81 Billion minus current liabilities of CN¥5.19 Billion) is measured against net assets of CN¥15.18 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. See Pharmaron Beijing Co Ltd (300759) net asset quality to measure how much of total assets are equity-financed.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Pharmaron Beijing Co Ltd Working Capital to Net Assets (2014–2024)
This chart shows how Pharmaron Beijing Co Ltd's Working Capital to Net Assets ratio has evolved across 11 annual periods from 2014 to 2024. As of September 2025, the ratio stands at 17.3%, reflecting working capital of CN¥2.62 Billion against net assets of CN¥15.18 Billion CNY. Check Pharmaron Beijing Co Ltd tangible book value ratio to evaluate the tangible quality of the company's equity base.
Annual Working Capital to Net Assets for Pharmaron Beijing Co Ltd (2014–2024)
The table below presents the year-by-year Working Capital to Net Assets ratio for Pharmaron Beijing Co Ltd from 2014 to 2024, covering 11 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For live market cap and the full company profile, see 300759 company net worth.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2024 | 23.8% | CN¥3.38 Billion | CN¥14.22 Billion | CN¥7.61 Billion | CN¥4.22 Billion | ▼ -30.7 pp |
| 2023 | 54.5% | CN¥7.22 Billion | CN¥13.24 Billion | CN¥10.87 Billion | CN¥3.65 Billion | ▲ +30.3 pp |
| 2022 | 24.2% | CN¥2.62 Billion | CN¥10.84 Billion | CN¥6.54 Billion | CN¥3.91 Billion | ▼ -30.8 pp |
| 2021 | 55.0% | CN¥5.66 Billion | CN¥10.30 Billion | CN¥8.64 Billion | CN¥2.98 Billion | ▲ +15.2 pp |
| 2020 | 39.8% | CN¥3.56 Billion | CN¥8.93 Billion | CN¥5.54 Billion | CN¥1.98 Billion | ▼ -19.8 pp |
| 2019 | 59.6% | CN¥4.67 Billion | CN¥7.84 Billion | CN¥5.94 Billion | CN¥1.27 Billion | ▲ +58.6 pp |
| 2018 | 1.1% | CN¥24.85 Million | CN¥2.34 Billion | CN¥1.28 Billion | CN¥1.26 Billion | ▼ -5.8 pp |
| 2017 | 6.8% | CN¥137.16 Million | CN¥2.01 Billion | CN¥1.08 Billion | CN¥941.02 Million | ▼ -17.9 pp |
| 2016 | 24.7% | CN¥436.28 Million | CN¥1.76 Billion | CN¥1.10 Billion | CN¥660.88 Million | ▲ +339.5 pp |
| 2015 | -314.7% | CN¥-530.11 Million | CN¥168.43 Million | CN¥435.00 Million | CN¥965.11 Million | ▼ -222.1 pp |
| 2014 | -92.6% | CN¥-239.26 Million | CN¥258.25 Million | CN¥341.30 Million | CN¥580.56 Million | — |